Literature DB >> 28000028

Demonstration of the herd effect in adults after the implementation of pneumococcal vaccination with PCV13 in children.

C Hays1, Q Vermee1, A Agathine1, A Dupuis1, E Varon2, C Poyart1, M-C Ploy3, J Raymond4.   

Abstract

The purpose of this investigation was to describe the evolution of serotypes and antibiotic susceptibility of Streptococcus pneumoniae strains isolated from both adults and children from the same population area with invasive pneumococcal disease (IPD) or acute otitis media (AOM), 5 years after the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13). From 2009 to 2015, 839 strains of S. pneumoniae strains were collected (481 from adults and 358 from children). Serotyping by latex antisera and molecular methods was performed. Antimicrobial susceptibility was tested. Compared to 2009, the total number of strains isolated in 2015 decreased in children (263 vs. 53, respectively) and in adults (220 vs. 131, respectively). Serotype coverage of PCV13 for IPD decreased significantly in adults from 67.7% (149/220) to 25.2% (33/131) and in children from 75.1% (61/81) to 18.5% (5/27). Especially, serotypes 1, 7F and 19A decreased significantly in children, while serotypes 7F and 19A decreased significantly in adults. PCV13 serotypes involved in AOM decreased significantly over the 5-year period, from 85.7% (156/182) to 38.5% (10/26), and were more susceptible to penicillin, amoxicillin and cefotaxime, p < 0.05. Serotypes 8, 9N and 10A seemed to emerge in adults, whereas any serotype prevalence was observed in children. Between 2009 and 2015, the introduction of PCV13 has resulted in a significant decrease of the number of S. pneumoniae strains isolated from IPD in children as in adults. It highlights a strong herd effect of vaccination in adults.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28000028     DOI: 10.1007/s10096-016-2868-5

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  34 in total

1.  Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine.

Authors:  N Grall; O Hurmic; M Al Nakib; M Longo; C Poyart; M-C Ploy; E Varon; J Raymond
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-18       Impact factor: 3.267

2.  Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012.

Authors:  Andrea C Farnham; Christopher M Zimmerman; Vikki Papadouka; Kevin J Konty; Jane R Zucker; Geetha V Nattanmai; Sherly Jose; Jennifer B Rosen
Journal:  JAMA Pediatr       Date:  2015-07       Impact factor: 16.193

3.  Changes in childhood pneumonia and infant mortality rates following introduction of the 13-valent pneumococcal conjugate vaccine in Nicaragua.

Authors:  Sylvia Becker-Dreps; Erick Amaya; Lan Liu; Gilberto Moreno; Julio Rocha; Rafaela Briceño; Jorge Alemán; Michael G Hudgens; Christopher W Woods; David J Weber
Journal:  Pediatr Infect Dis J       Date:  2014-06       Impact factor: 2.129

Review 4.  Epidemiological differences among pneumococcal serotypes.

Authors:  William P Hausdorff; Daniel R Feikin; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2005-02       Impact factor: 25.071

5.  Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.

Authors:  A Lepoutre; E Varon; S Georges; F Dorléans; C Janoir; L Gutmann; D Lévy-Bruhl
Journal:  Vaccine       Date:  2014-11-20       Impact factor: 3.641

6.  Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.

Authors:  Chamira Rodrigo; Thomas Bewick; Carmen Sheppard; Sonia Greenwood; Tricia M Mckeever; Caroline L Trotter; Mary Slack; Robert George; Wei Shen Lim
Journal:  Eur Respir J       Date:  2015-03-18       Impact factor: 16.671

7.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

8.  Increase of serotypes 15A and 23B in IPD in Germany in the PCV13 vaccination era.

Authors:  Mark van der Linden; Stephanie Perniciaro; Matthias Imöhl
Journal:  BMC Infect Dis       Date:  2015-05-05       Impact factor: 3.090

9.  Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.

Authors:  Gabriela García Gabarrot; Mariana López Vega; Gabriel Pérez Giffoni; Silvia Hernández; Pablo Cardinal; Viviana Félix; Jean Marc Gabastou; Teresa Camou
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

Review 10.  Pneumococcal serotype evolution in Western Europe.

Authors:  Myint Tin Tin Htar; Dina Christopoulou; Heinz-Josef Schmitt
Journal:  BMC Infect Dis       Date:  2015-10-14       Impact factor: 3.090

View more
  8 in total

Review 1.  Streptococcus pneumoniae Otitis Media Pathogenesis and How It Informs Our Understanding of Vaccine Strategies.

Authors:  Caroline Bergenfelz; Anders P Hakansson
Journal:  Curr Otorhinolaryngol Rep       Date:  2017-05-20

2.  Overview of pneumococcal serotypes and genotypes causing diseases in patients with chronic obstructive pulmonary disease in a Spanish hospital between 2013 and 2016.

Authors:  Hisashi Shoji; Daniel A Vázquez-Sánchez; Aida Gonzalez-Diaz; Meritxell Cubero; Fe Tubau; Salud Santos; Dolores García-Somoza; Josefina Liñares; José Yuste; Sara Martí; Carmen Ardanuy
Journal:  Infect Drug Resist       Date:  2018-09-04       Impact factor: 4.003

Review 3.  Revisiting cefditoren for the treatment of community-acquired infections caused by human-adapted respiratory pathogens in adults.

Authors:  María-José Giménez; Lorenzo Aguilar; Juan José Granizo
Journal:  Multidiscip Respir Med       Date:  2018-11-02

4.  Decreased relative risk of pneumococcal pneumonia during the last decade, a nested case-control study.

Authors:  Carlos M Luna; Laura Pulido; Michael S Niederman; Alberto Casey; Diego Burgos; Sebastián D Leiva Agüero; Alejandra Grosso; Evangelina Membriani; Andrea C Entrocassi; Marcelo Rodríquez Fermepin; Carlos A Vay; Susana Garcia; Angela Famiglietti
Journal:  Pneumonia (Nathan)       Date:  2018-09-25

5.  Vaccination of Icelandic Children with the 10-Valent Pneumococcal Vaccine Leads to a Significant Herd Effect among Adults in Iceland.

Authors:  Sigríður J Quirk; Gunnsteinn Haraldsson; Martha Á Hjálmarsdóttir; Andries J van Tonder; Birgir Hrafnkelsson; Stephen D Bentley; Ásgeir Haraldsson; Helga Erlendsdóttir; Angela B Brueggemann; Karl G Kristinsson
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

6.  The Impact of Pneumococcal Conjugate Vaccine (PCV) Coverage Heterogeneities on the Changing Epidemiology of Invasive Pneumococcal Disease in Switzerland, 2005-2019.

Authors:  Oluwaseun Rume-Abiola Oyewole; Phung Lang; Werner C Albrich; Kerstin Wissel; Stephen L Leib; Carlo Casanova; Markus Hilty
Journal:  Microorganisms       Date:  2021-05-18

7.  Streptococcus pneumoniae Serotypes Carried by Young Children and Their Association With Acute Otitis Media During the Period 2016-2019.

Authors:  Esra Ekinci; Stefanie Desmet; Liesbet Van Heirstraeten; Colette Mertens; Ine Wouters; Philippe Beutels; Jan Verhaegen; Surbhi Malhotra-Kumar; Heidi Theeten
Journal:  Front Pediatr       Date:  2021-07-05       Impact factor: 3.418

8.  Effects of Pneumococcal Conjugate Vaccine on Genotypic Penicillin Resistance and Serotype Changes, Japan, 2010-2017.

Authors:  Kimiko Ubukata; Misako Takata; Miyuki Morozumi; Naoko Chiba; Takeaki Wajima; Shigeo Hanada; Michi Shouji; Megumi Sakuma; Satoshi Iwata
Journal:  Emerg Infect Dis       Date:  2018-11       Impact factor: 6.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.